Regulatory ProfessionalsRegulatory ProfessionalsRegulatory ProfessionalsRegulatory Professionals
  • About Us
    • Our Story
    • Leadership
    • Senior Consultants
  • Services
    • Overview
    • Product Development Services
    • Regulatory Consulting Services
    • Electronic Publishing | eCTD
    • Medical and Regulatory Writing
    • Nonclinical Consulting Services
    • CMC Consulting Services
    • Quality Assurance
    • Project Management
    • Electronic Trial Master Files
  • Resources
    • Blog
    • White Papers
    • Webinars
    • News
  • Careers
  • Contact

The FDA Is Ending Its Rare Pediatric Disease Priority Review Vouchers – and Time Is Running Out to Get One

By Irene Figari | Blog, Regulatory Affairs | Comments are Closed | 31 July, 2020 | 1

Between 2010 and 2018, 33.8 percent of the 402 orphan indications approved by the FDA were approved for children only or targeted pediatric diseases.[1] The rare pediatric disease priority review voucher program is one incentive that’s helped to spur research and development in this area with more than 20 vouchers granted to date.

While it is set to expire on September 30, 2020, there is still time for sponsors to request the rare pediatric disease designation that makes a drug eligible for the program. A drug must have rare pediatric disease designation granted by this date and then gain approval for the priority review voucher itself no later than September 30, 2022. 

The FDA guarantees a 60-day review timeline of rare pediatric disease designation requests when issued alongside a fast track or orphan designation request. As a result, the FDA has announced that it cannot commit to responding by the program deadline for applications received after July 31, 2020. However, sponsors who believe their product is eligible are still encouraged to apply – the sooner, the better. Here’s what you need to know to understand your product’s eligibility and maximize your chance of a successful submission.

Benefits of the priority review voucher program for rare disease sponsors

Under the Orphan Drug Act of 1983, companies targeting treatment options for rare diseases are eligible for several additional years of exclusivity in their treatment options without competition from generic alternatives. The priority review voucher program for rare pediatric disease drugs provides an additional benefit by shortening the FDA drug submission review process from the standard ten months to six; however, the priority review process does not require approval within this timeframe.

Eligible candidates are given two separate vouchers, each of which has priority review: one voucher is used for the drug treating the rare disease while the other one can be used for another indication. While the priority review voucher program for rare pediatric diseases is expiring on September 30, 2020, the vouchers themselves do not expire once granted.

Who’s eligible for priority review?

The FDA has published a list of rare diseases that qualify for priority review on its website. For a company to be awarded a priority review voucher, the application must be for a disease that is listed on their website OR another disease that qualifies under the Orphan Drug Act. In addition, the request for a priority review voucher cannot contain an active ingredient that has been approved in any other application. This includes esters and salts of active ingredients.

Improving your chances of a successful submission

To improve the chances of a successful submission, companies should ensure the disease they intend to research has been listed on the FDA website, as this will make the approval process easier. It is also important to review other treatments that are being actively researched. In order to be approved, research cannot match another ingredient that is already under development.

If you are looking to submit a request for rare pediatric disease designation, Regulatory Professionals, A Division of Premier Research, can help. We provide a thorough analysis of the issues and a comprehensive assessment of the regulatory environment to help you enter Agency discussions with strategies to minimize risk and maximize successful negotiations. Contact us today to learn more.


[1] Kimmel L, Conti RM, Volerman A, Chua KP. Pediatric Orphan Drug Indications: 2010-2018. Pediatrics. 2020;145(4):e20193128. doi:10.1542/peds.2019-3128

FDA, FDA submissions, orphan drugs, pediatrics, rare disease
Avatar

Irene Figari

More posts by Irene Figari

Related Post

  • Outsourcing-Pharma.com: Holistic Approach Benefits Drug Development

    By Sameena Sharif | Comments are Closed

    Read Now

  • 5 Tips to Avoid an IND Clinical Hold: Regulatory Guidance and Insights

    By Aurora Sosa | Comments are Closed

    Read Now

  • Creating a Compliant eCTD: Avoiding Common Regulatory and Technical Pitfalls on the Path to Submission

    By Valerie Bright | Comments are Closed

    Read Now

  • PODCAST: COVID-19 Update: What Sponsors Need to Know About the New FDA Guidance

    By Nach Davé | Comments are Closed

    Listen Now

  • Statistical Considerations for FDA COVID-19 Guidance

    By Shari Medendorp | Comments are Closed

    Read Now

Recent Posts

  • Product Development Checklist: Considerations for Each Stage of the Drug Development Process
  • Key Changes in the Revised EMA Guidance on Clinical Trials During COVID
  • Advancing Patient Healthcare: Clarifying the 2019 Changes in India’s Drug and Clinical Trial Rules
  • The First Step for Streamlined CMC Development: Optimize the Target Product Profile
  • Speed vs Safety: How Regulators Are Sizing Up Evidence Today

Categories

  • Blog
  • CMC
  • COVID-19
  • FDA
  • INTERACT Meeting
  • News
  • Podcast
  • Regulatory Affairs
  • Webinars
  • White Papers
April 2021
M T W T F S S
« Mar    
 1234
567891011
12131415161718
19202122232425
2627282930  

Headquarters

8000 Jarvis Ave.
Suite 100
Newark, CA 94560

North Carolina

3800 Paramount Parkway
Suite 400
Morrisville, NC 27560-6949

 

San Diego

Aventine Building
8910 University Center Lane
Suite 400 San Diego, CA 92122

United Kingdom

250 South Oak Way
Green Park
Reading, Berkshire, RG2 6UG

Australia

Ground Floor
23 Milton Parade
Malvern VIC 3144

  • About Us
  • Cookie Policy
  • Privacy Notice
  • Contact
Copyright 2021 Regulatory Professionals | All Rights Reserved
  • About Us
    • Our Story
    • Leadership
    • Senior Consultants
  • Services
    • Overview
    • Product Development Services
    • Regulatory Consulting Services
    • Electronic Publishing | eCTD
    • Medical and Regulatory Writing
    • Nonclinical Consulting Services
    • CMC Consulting Services
    • Quality Assurance
    • Project Management
    • Electronic Trial Master Files
  • Resources
    • Blog
    • White Papers
    • Webinars
    • News
  • Careers
  • Contact
Regulatory Professionals
XWe use cookies (and equivalent technologies) to collect and analyze information on our Website’s performance and to enable the Website to function. Cookies also allow us and third parties to tailor the ads you see when you visit our Website and other third party websites in the same online network, including social networks. By clicking ‘AGREE', you agree to these uses of cookies. If you do not agree or if you would like more information, you can manage your cookie preferences by clicking on 'Cookie Settings'. Cookie Policy REJECTAGREECookie Settings
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non Necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Save & Accept